Clinical and Genomic Characterization of Secondary Rectal Cancer After Radiotherapy for Prostate Cancer

被引:0
|
作者
Omer, Dana M. [1 ]
Shah, Farheen [1 ,2 ]
Luthra, Anisha [2 ]
Chen, Chin-Tung [1 ]
Lee, Christina I. [1 ]
Williams, Hannah [1 ]
Walch, Henry [2 ]
Verheij, Floris S. [1 ]
Rosen, Roni [1 ]
Alvarez, Janet [1 ]
Firat, Canan [3 ]
Karagkounis, Georgios [1 ]
Weiser, Martin R. [1 ]
Widmar, Maria [1 ]
Wei, Iris H. [1 ]
Pappou, Emmanouil P. [1 ]
Nash, Garrett M. [1 ]
Smith, J. Joshua [1 ]
Chatila, Walid K. [2 ]
Romesser, Paul B. [4 ]
Shia, Jinru [3 ]
Paty, Philip B. [1 ]
Garcia-Aguilar, Julio [1 ]
Sanchez-Vega, Francisco [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Colorectal Serv, New York, NY USA
关键词
MUTATIONAL SIGNATURES; RADIATION-THERAPY; RISK; LANDSCAPE; BLADDER; IMPACT;
D O I
10.1001/jamanetworkopen.2025.1039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Patients treated with radiotherapy (RT) for prostate cancer (PC) have increased risk of secondary rectal cancer (SRC) and more limited treatment options. Objective To assess the tumor molecular profile, clinical characteristics, and oncologic outcomes of SRC after PC and compare them with those of primary rectal cancer (PRC). Design, Setting, and Participants This case-control study included patients with SRC diagnosed 5 or more years after RT for PC and patients with PRC who were treated at Memorial Sloan Kettering Cancer Center in New York between February 1, 1994, and September 31, 2022. Main Outcomes and Measures Clinical information and DNA sequencing data were analyzed. Oncologic outcomes were compared between patients with SRC and clinically matched patients with PRC using log-rank tests and Cox proportional hazards regression models. Numerical and categorical variables were compared using the Wilcoxon rank sum test and Fisher exact test, respectively. Results The analysis included 604 male patients with PRC (71.6%; median age, 55 [IQR, 46-66] years) and 64 male patients with SRC (median age, 78 [IQR, 72-82] years). Patients with SRC had more distal rectum (37 of 63 [58.7%] vs 131 of 581 [22.5%]; P < .001) and anterior rectal wall (20 of 57 [35.1%] vs 67 of 496 [13.5%]; P < .001) tumors, were less likely to receive neoadjuvant treatment (33 of 64 [51.6%] vs 570 of 604 [94.4%]), and had shorter 5-year overall survival (45.7% vs 64.9%; P = .01) and disease-free survival (40.3% vs 71.2%; P = .006) compared with clinically matched patients with PRC. Targeted DNA sequencing data from 31 SRC tumors identified lower mutational burden (median, 4.4 [IQR, 3.2-6.7] per megabase [Mb] vs 5.8 [IQR, 4.4-7.0] per Mb; P = .047), lower frequency of APC alterations (15 [48.4%] vs 432 [79.9%]; P < .001), and higher rates of SMAD4 inactivation (8 [25.8%] vs 54 [10.0%]; P = .01) compared with 541 PRC tumors. Whole-exome sequencing data from 17 SRC tumors identified a higher rate of frameshift deletions compared with 28 PRC tumors (median, 5.0 [IQR, 4.0-9.0] vs 2.5 [IQR, 1.0-4.2] variants; P < .001). Conclusions and Relevance In this case-control study, patients with SRC after RT for PC had worse survival and different molecular profiles than patients with PRC. These findings may help improve the clinical management of SRC.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] A Population-Based Study of Secondary Prostate Cancer Risk after Radiotherapy in Male Patients with Rectal Cancer: A Retrospective Cohort Study
    Chuang, Jen-Pin
    Lee, Yen-Chien
    Lee, Jenq-Chang
    Lu, Chin-Li
    Li, Chung-Yi
    MEDICINA-LITHUANIA, 2019, 55 (04):
  • [22] Clinical Correlations between Treatment with Anticoagulants/Antiaggregants and Late Rectal Toxicity after Radiotherapy for Prostate Cancer
    Takeda, Ken
    Ogawa, Yoshihiro
    Ariga, Hisanori
    Koto, Masashi
    Sakayauchi, Toru
    Fujimoto, Keisuke
    Narazaki, Kakutaro
    Mitsuya, Masatoshi
    Takai, Yoshihiro
    Yamada, Shogo
    ANTICANCER RESEARCH, 2009, 29 (05) : 1831 - 1834
  • [23] Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies
    Bergerot, Paulo Gustavo
    Nelson, Rebecca A.
    Ye, Da-Wei
    Grivas, Petros
    Singh, Parminder
    Agarwal, Neeraj
    Choueiri, Toni K.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [24] Secondary Cancers After Radiation Therapy for Primary Prostate or Rectal Cancer
    Yen-Chien Lee
    Chung-Cheng Hsieh
    Chung-Yi Li
    Jen-Pin Chuang
    Jenq-Chang Lee
    World Journal of Surgery, 2016, 40 : 895 - 905
  • [25] Secondary Cancers After Radiation Therapy for Primary Prostate or Rectal Cancer
    Lee, Yen-Chien
    Hsieh, Chung-Cheng
    Li, Chung-Yi
    Chuang, Jen-Pin
    Lee, Jenq-Chang
    WORLD JOURNAL OF SURGERY, 2016, 40 (04) : 895 - 905
  • [26] Secondary cancer after radiotherapy for prostate cancer: Should we be more aware of the risk?
    Bostrom, Peter J.
    Soloway, Mark S.
    EUROPEAN UROLOGY, 2007, 52 (04) : 973 - 982
  • [27] Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer
    Shiota, Masaki
    Yokomizo, Akira
    Takeuchi, Ario
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Ohga, Saiji
    Sasaki, Tomonari
    Nakamura, Katsumasa
    Honda, Hiroshi
    Eto, Masatoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (10) : 952 - 957
  • [28] Genomic and clinical characterization of stromal infiltration markers in prostate cancer
    Mahal, Brandon A.
    Alshalalfa, Mohammed
    Zhao, Shuang G.
    Beltran, Himisha
    Chen, William S.
    Chipidza, Fallon
    Davicioni, Elai
    Karnes, R. Jeffrey
    Ku, Sheng-Yu
    Lotan, Tamara L.
    Muralidhar, Vinayak
    Rebbeck, Timothy R.
    Schaeffer, Edward M.
    Spratt, Daniel E.
    Feng, Felix Y.
    Nguyen, Paul L.
    CANCER, 2020, 126 (07) : 1407 - 1412
  • [29] Rectal bleeding and radiotherapy for prostate cancer. DVHs and potential clinical parameters
    Pellizzon, A. C. A.
    Silva, M.
    Fogaroli, R.
    Godim, G.
    Chen, M.
    Guedes, D.
    Rosa, R. G. D. S.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S426 - S426
  • [30] Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer
    Pinkawa, Michael
    Berneking, Vanessa
    Konig, Liane
    Frank, Dilini
    Bretgeld, Marilou
    Eble, Michael J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (01) : 22 - 28